Application prospect of glucagon-like peptide-1 receptor agonists in cardiovascular diseases

Diabetes is an independent risk factor for cardiovascular events and increases the risk of death in patients with cardiovascular diseases. Novel glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been proved to significantly reduce the incidence of cardiovascular events in patients with type 2 diabetes and the mechanisms may be related to anti-atherosclerosis, attenuation of inflammatory response, improvement of endothelial functions, suppression of appetite and weight loss. This article reviews recent progress of glucagon-like peptide-1 receptor agonists in the prevention and treatment of cardiovascular diseases and provides new ideas for treatment.